Obecabtagene autoleucel in lupus: Evidence and ongoing trials

The Lupus Hub was pleased to speak with David Jayne, University of Cambridge, UK. We asked, What is the current evidence supporting obecabtagene autoleucel for the treatment of lupus, and what clinical trials are ongoing?  

During this interview, Jayne discusses the scientific rationale and emerging clinical evidence supporting CD19-directed CAR T-cell therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). He highlights the preliminary safety and efficacy data for obecabtagene autoleucel (obe-cel), ongoing clinical trials, and the opportunities and challenges associated with integrating CAR T-cell therapy into routine care. 

Key Learnings:

• Despite advancements in treatment options for lupus, an unmet need remains for therapies that provide sustained treatment-free remission, as most patients experience a chronic relapsing disease course and cumulative treatment-related toxicity. 
• Approved B-cell-directed therapies, including belimumab (B-lymphocyte stimulator [BLyS] inhibitor) and obinutuzumab (anti-CD20 monoclonal antibody), validate the role of B cells in lupus pathogenesis; however, their efficacy is partial, and disease relapse commonly occurs following treatment withdrawal.^1–4 
• Anti-CD19 CAR T-cell therapy aims to achieve deeper B-cell depletion, including within lymphoid organs and affected tissues, leading to a B-cell reset and reconstitution of a more homeostatic, less pathogenic B-cell repertoire.⁵ 
• In an open-label, phase I study (CARLYSLE; NCT06333483), obe-cel (50 × 10⁶ CAR T cells) demonstrated a manageable safety profile in 6 patients with SLE, with cytokine release syndrome limited to mild-to-moderate severity.⁶ 
• Preliminary efficacy data suggest that obe-cel may induce treatment-free remission, facilitate withdrawal of lupus therapies, particularly glucocorticoids, and eliminate pathogenic autoantibodies. 
• Positive phase I data have supported progression to an ongoing prospective trial of obe-cel in patients with refractory Class III/IV LN (LUMINA; NCT07053800) who have had an inadequate response to at least two standard immunosuppressive therapies, including mycophenolate, voclosporin, or belimumab.⁷ 
• Patients with refractory LN represent a population at high risk of progression to end-stage kidney disease and may derive substantial benefit from CAR T-cell therapies.⁴ 
• Successful implementation of CAR T-cell therapy requires close multidisciplinary collaboration between cell therapy, hematology/oncology, rheumatology, and nephrology teams. 
• Although CAR T-cell therapy remains resource-intensive, current evidence supports anti-CD19 CAR T as a promising proof-of-concept approach, with future efforts focused on streamlining the process, reducing hospitalization, and optimizing monitoring strategies. 

This educational resource is independently supported by Autolus. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.